- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02976831
Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects
A Phase I Randomized Single-blind Placebo-controlled 2-part Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 Following Single and Multiple Ascending Dose Administration to Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, HA1 3UJ
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated, written informed consent prior to any study specific procedures.
- Healthy male and/or female subjects aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venipuncture.
Females must have a negative pregnancy test at screening and on admission to the Unit, must not be lactating and must be of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria.
- Post-menopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and FSH levels in the post-menopausal range.
- Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation.
- Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
- Hormone replacement therapy is not allowed for females to exclude any drug-drug interaction between the hormone replacement therapy and AZD0284
Exclusion Criteria:
- History of any clinically significant disease or disorder which, in the opinion of the PI, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- Any clinically significant illness, infection, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.
- Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the PI.
- Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV).
Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:
- Systolic BP (SBP) < 90 mmHg or ≥ 140 mmHg
- Diastolic BP (DBP) < 50 mmHg or ≥ 90 mmHg
- Pulse < 45 or > 85 beats per minute (bpm)
- Any clinically significant abnormalities in rhythm, conduction or morphology of the resting ECG and any clinically important abnormalities in the 12 Lead ECG as considered by the PI that may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology, particularly in the protocol defined primary lead or left ventricular hypertrophy. Prolonged QT interval corrected for heart rate using Fridericia's formula (QTcF) > 450 ms or shortened QTcF < 340 ms or family history of long QT syndrome.
- PR(PQ) interval shortening < 120 ms (PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular pre-excitation)
- PR (PQ) interval prolongation (> 240 ms) intermittent second (Wenckebach block while asleep is not exclusive) or third degree atrioventricular (AV) block, or AV dissociation.
- Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS > 110 ms. Subjects with QRS > 110 ms but < 115 ms are acceptable if there is no evidence of e.g. ventricular hypertrophy or pre-excitation
- Known or suspected history of drug abuse, as judged by the PI
- Current smokers or those who have smoked or used nicotine products within the previous 3 months.
- History of alcohol abuse or excessive intake of alcohol, as judged by the PI.
- Positive screen for drugs of abuse or cotinine (nicotine) at screening or admission to the Unit or positive screen for alcohol on admission to the Unit prior to the first administration of IMP.
- History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD0284.
- Excessive intake of caffeine containing drinks or food (e.g., coffee, tea, chocolate), as judged by the PI.
- Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
- Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life.
- Plasma donation within one month of screening or any blood donation/blood loss > 500 mL during the 3 months prior to screening
- Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of investigational product in this study. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest. Note: subjects consented and screened, but not randomized in this study or a previous Phase I study, are not excluded.
- Receipt of live viral or live bacterial vaccines (such as BCG) 3 months prior to randomization on Day 1.
- Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order
- Subjects who have previously received AZD0284
- Involvement of any Astra Zeneca or study site employee or their close relatives.
- Judgment by the PI that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
- Subjects who are vegans or have medical dietary restrictions.
- Subjects who cannot communicate reliably with the PI.
Subject who have increased risk of infection
- History and/or presence of tuberculosis (TB); positive result for IFN-γ release assay (IGRA) (i.e. QuantiFERON TB-Gold) the test may be repeated if the initial test result is indeterminate. Subjects who have resided in regions where tuberculosis or mycosis are endemic during 90 days before screening or who intend to visit such a region during the duration of the study.
- Is in a high-risk group for HIV infection within the last 6 months.
- Subjects with active malignancy or neoplastic disease in the previous 5 years other than superficial basal cell carcinoma.
- Subjects who have received live or attenuated vaccine in the 4 weeks prior to dosing.
- Subjects with a disease history suggesting abnormal immune function.
In addition, the following is considered a criterion for the exclusion from the optional genetic component of the study:
- Previous bone marrow transplant.
- Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection or previous bone marrow transplant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AZD0284
Part 1A: Following an overnight fast of at least 10 hours, each subject will receive a single dose of AZD0284 or matching placebo in the form of an oral solution with water. The total volume that the subject will receive (IMP and water) will be 240 mL. Part 1B (food cohort): Subjects, will receive a single dose of AZD0284 at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing. The total volume that the subject will receive (IMP and water) will be 240 mL. Part 2: In Part 2, subjects will receive 1 dose level of AZD0284 (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (IMP with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1. |
Oral solution, concentration: 2 mg/mL and 15 mg/mL
|
Active Comparator: Placebo
Part 1A: Following an overnight fast of at least 10 hours, each subject will receive a single dose of placebo in the form of an oral solution with water. The first cohort will receive 4.0 mg AZD0284 or placebo on Day 1. The actual dose for subsequent cohorts will be determined after review of all available safety or other pertinent data from the previous dose by the SRC Part 1B (food cohort): In Part 1B, subjects, will receive a single dose of placebo at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing. Part 2: In Part 2, each subject will receive 1 dose level of placebo (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (placebo with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1. |
Placebo matching AZD0284 in the form of an oral solution with water.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of AZD0284 following single dosing (Part 1) and multiple ascending oral dosing (Part 2) assessed by recording the number of adverse events.
Time Frame: From Screening till Visit 3 (5 to 7 days post final dose)
|
Standard adverse event collection.
An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.
|
From Screening till Visit 3 (5 to 7 days post final dose)
|
Safety and tolerability of AZD0284 following single dosing (Part 1) and multiple ascending oral dosing (Part 2) assessed by recording the supine vital signs (BP [supine and standing], pulse and oral body temperature).
Time Frame: From Screening till Visit 3 (5 to 7 days post final dose)
|
The following variables will be collected after the subject has rested in the supine position for at least 5 minutes:
|
From Screening till Visit 3 (5 to 7 days post final dose)
|
Safety and tolerability of AZD0284 following single dosing (Part 1) and multiple ascending oral dosing (Part 2) assessed by electrocardiogram (ECG).
Time Frame: From Screening till Visit 3 (5 to 7 days post final dose)
|
A 12-lead ECG will be obtained after the subject rested in the supine position for at least 10 minutes (using the sites own ECG machines when not performing dECGs and using the same machine as the dECGs when time points coincide).
|
From Screening till Visit 3 (5 to 7 days post final dose)
|
Safety and tolerability of AZD0284 following single dosing (Part 1) and multiple ascending oral dosing (Part 2) assessed by digital ECG (dECG)
Time Frame: From Screening till Visit 3 (5 to 7 days post final dose)
|
From Screening till Visit 3 (5 to 7 days post final dose)
|
|
Safety and tolerability of AZD0284 following single dosing (Part 1) and multiple ascending oral dosing (Part 2) assessed by telemetry
Time Frame: From Screening till Visit 3 (5 to 7 days post final dose)
|
From Screening till Visit 3 (5 to 7 days post final dose)
|
|
Safety and tolerability of AZD0284 following single dosing (Part 1) and multiple ascending oral dosing (Part 2) by physical examination and laboratory assessments (hematology, clinical chemistry and urinalysis).
Time Frame: From Screening till Visit 3 (5 to 7 days post final dose)
|
The complete physical examinations will include an assessment of the general appearance, skin, cardiovascular, respiratory, abdomen, head, and neck (including ears, eyes, nose, and throat), lymph nodes, thyroid, musculoskeletal and neurological systems.
|
From Screening till Visit 3 (5 to 7 days post final dose)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics: Observed maximum concentration, taken directly from the individual concentration-time curve (Cmax) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Effect of food on the bioavailability of AZD0284.
Time Frame: From Day 1 till Follow up Visit (5 to 7 days post final dose)
|
From Day 1 till Follow up Visit (5 to 7 days post final dose)
|
|
Presence and extent of renal clearance of AZD0284.
Time Frame: Days 1,2, and 3
|
The presence and extent of renal clearance of AZD0284 will be assessed by measuring the drug concentrations in urine.
|
Days 1,2, and 3
|
Confirmation of Proof of Mechanism (PoM) of AZD0284.
Time Frame: Screening, Day 1, Day 2 and Day 3
|
The Proof of Mechanism (PoM) will be confirmed by demonstrating that oral dosing of AZD0284 reduces IL-17 secretion by ex vivo stimulated whole blood T cells.
|
Screening, Day 1, Day 2 and Day 3
|
Pharmacokinetics: Time to reach maximum concentration, taken directly from the individual concentration-time curve (tmax) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: Terminal half-life, estimated as (ln2)/λz (t1/2λz) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: Terminal rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (λz) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUClast) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: Area under the plasma concentration-time curve from time zero to t hours after dosing (AUC0-t) of of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: Area under the concentration-time curve from time zero extrapolated to infinity. AUC is estimated by AUC(0-last) + Clast/λz where Clast is the last observed quantifiable concentration (AUC) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: Apparent volume of distribution for parent drug at steady state, estimated by dividing the Mean Residence Time (MRT) by the apparent clearance (CL/F) (Vss/F) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: Apparent volume of distribution for parent drug at terminal phase (extravascular administration), estimated by dividing the apparent clearance (CL/F) by λz (Vz/F) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: Apparent clearance for parent drug estimated as dose divided by AUC (CL/F) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: AUC divided by the dose administered (AUC/D) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: AUC0-t divided by the dose administered (AUC0-t/D) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: Cmax divided by the dose administered (Cmax/D) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: Mean Residence Time (MRT) of AZD0284.
Time Frame: Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1A and Part 1B: From Day 1 to Day 4 ( at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: Ratio of the fed AUC divided by the fasted AUC (Rfed/fasted AUC) of AZD0284.
Time Frame: Part 1B: From Day 1 to Day 4 during Treatment Period 2 (at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
Part 1B: From Day 1 to Day 4 during Treatment Period 2 (at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose).
|
|
Pharmacokinetics: Ratio of the fed Cmax divided by the fasted Cmax (Rfed/fasted Cmax) of AZD0284
Time Frame: Part 1B: From Day 1 to Day 4 during Treatment Period 2 (at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose)
|
Part 1B: From Day 1 to Day 4 during Treatment Period 2 (at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose)
|
|
Pharmacokinetics: Area under the plasma concentration-time curve in the dosing interval (AUCτ) of AZD0284.
Time Frame: Day 1
|
Day 1
|
|
Pharmacokinetics: AUClast divided by the dose administered (AUClast/D) of AZD0284.
Time Frame: Day 1
|
Day 1
|
|
Pharmacokinetics: Observed concentration at the end of the dosing interval (Cmin) of AZD0284.
Time Frame: Day 1
|
Day 1
|
|
Pharmacokinetics: AUCτ divided by the dose administered (AUCτ /D) of AZD0284.
Time Frame: Day 1
|
Day 1
|
|
Pharmacokinetics: Accumulation ratio for AUCτ estimated by dividing AUCτ from the last dosing day by AUCτ on Day 1 (Rac AUCτ), of AZD0284
Time Frame: Day 1
|
Day 1
|
|
Pharmacokinetics: Accumulation ratio for Cmax , estimated by dividing Css,max from the last dosing day by Cmax on Day 1 (Rac Cmax), of AZD0284
Time Frame: Day 1
|
Day 1
|
|
Pharmacokinetics: Temporal change, estimated by dividing AUCτ from the last dosing day by AUC on Day 1 (TCP)of AZD0284
Time Frame: Day 1
|
Day 1
|
|
Pharmacokinetics: Amount of analyte excreted into the urine from time t1 to t2 (Ae[t1-t2]) of AZD0284
Time Frame: Day 1
|
Urine collection for PK analyses will be performed in Cohort 4.
|
Day 1
|
Pharmacokinetics: Cumulative amount of unchanged drug excreted in urine from time zero to time after dosing (Ae[0-t]) of AZD0284
Time Frame: Day 1
|
Urine collection for PK analyses will be performed in Cohort 4.
|
Day 1
|
Pharmacokinetics: Fraction of dose excreted in urine from time t1 to t2, estimated by dividing Ae(t1-t2) by dose (fe [t1-t2]) of AZD0284
Time Frame: Day 1
|
Urine collection for PK analyses will be performed in Cohort 4.
|
Day 1
|
Pharmacokinetics: Percentage of dose excreted unchanged into the urine from time zero to time t, estimated by dividing Ae(0-t) by dose * 100 (fe[0-t]%)of AZD0284
Time Frame: Day 1
|
Urine collection for PK analyses will be performed in Cohort 4
|
Day 1
|
Pharmacokinetics: Renal clearance (CLR) of AZD0284
Time Frame: Day 1
|
Urine collection for PK analyses will be performed in Cohort 4.
|
Day 1
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D7800C00001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plaque Psoriasis Vulgaris
-
LEO PharmaCompletedPlaque Psoriasis | Psoriasis VulgarisGermany
-
SoligenixRecruitingPsoriasis | Plaque Psoriasis | Psoriasis VulgarisUnited States
-
LEO PharmaTerminatedPsoriasis | Plaque Psoriasis | Psoriasis VulgarisBelgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
-
AstraZenecaCompleted
-
PRCL Research Inc.CompletedPlaque Psoriasis | Psoriasis VulgarisCanada, Slovakia, Ukraine
-
University of California, San FranciscoTerminatedPlaque Psoriasis | Psoriasis VulgarisUnited States
-
AstraZenecaTerminatedPlaque Psoriasis VulgarisDenmark
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma SRLRecruitingModerate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis | Mixed Guttate/Plaque PsoriasisUnited States, Canada, Puerto Rico
Clinical Trials on AZD0284
-
AstraZenecaCompleted
-
AstraZenecaTerminatedPlaque Psoriasis VulgarisDenmark